玻璃体腔内注射抗血管内皮生长因子治疗早产儿视网膜病复发的危险因素分析

郝庆飞; 陈静; 阮鹏; 李高攀; 张静; 陈浩明; 郭宏湘; 孙晓娟; 程秀永

doi:10.7499/j.issn.1008-8830.2205011

PDF(572 KB)

HTML

中国当代儿科杂志 ›› 2022, Vol. 24 ›› Issue (11) : 1207-1212. DOI: 10.7499/j.issn.1008-8830.2205011

论著·临床研究

玻璃体腔内注射抗血管内皮生长因子治疗早产儿视网膜病复发的危险因素分析

郝庆飞, 陈静, 阮鹏, 李高攀, 张静, 陈浩明, 郭宏湘, 孙晓娟, 程秀永

作者信息 +

Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity

HAO Qing-Fei, CHEN Jing, RUAN Peng, LI Gao-Pan, ZHANG Jing, CHEN Hao-Ming, GUO Hong-Xiang, SUN Xiao-Juan, CHENG Xiu-Yong

Author information +

文章历史 +

摘要

目的探讨玻璃体腔内注射抗血管内皮生长因子（vascular endothelial growth factor，VEGF）治疗早产儿视网膜病（retinopathy of prematurity，ROP）的效果及复发的危险因素。方法回顾性收集2016年1月—2021年12月在郑州大学第一附属医院出生行抗VEGF治疗的ROP患儿159例的临床资料，根据首次抗VEGF治疗后随访周期内ROP复发与否分为复发组（24例）和非复发组（135例），比较分析2组临床资料，采用多因素logistic回归分析探讨抗VEGF治疗ROP复发的危险因素。结果经单次抗VEGF治疗后，所有159例患儿均显示附加病变消退。24例（15.1%）抗VEGF治疗后复发，复发平均时间为治疗后（8.4±2.6）周。多因素logistic回归分析显示，术前眼底出血、总用氧时间较长是ROP复发的危险因素（P<0.05），而妊娠高血压是保护因素（P<0.05）。结论玻璃体腔内注射抗VEGF治疗ROP是有效的。术前眼底出血和氧疗时间较长可增加ROP复发的风险，而对于妊娠高血压对ROP复发的影响，还需进一步研究证实。

Abstract

Objective To investigate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in the treatment of retinopathy of prematurity (ROP) and the risk factors for recurrence. Methods A retrospective analysis was performed on the medical data of 159 infants with ROP who were born in the First Affiliated Hospital of Zhengzhou University and underwent anti-VEGF treatment from January 2016 to December 2021. According to the presence or absence of recurrence within the follow-up period after initial anti-VEGF treatment, they were divided into a recurrence group with 24 infants and a non-recurrence group with 135 infants. The medical data were compared between the two groups, and a multivariate logistic regression analysis was used to investigate the risk factors for the recurrence of ROP after anti-VEGF treatment. Results After one-time anti-VEGF treatment, all 159 infants showed regression of plus disease. Recurrence was observed in 24 infants (15.1%) after anti-VEGF treatment, with a mean interval of (8.4±2.6) weeks from treatment to recurrence. The multivariate logistic regression analysis showed that preoperative fundus hemorrhage and prolonged total oxygen supply time were risk factors for the recurrence of ROP (P<0.05), while gestational hypertension was a protective factor (P<0.05). Conclusions Intravitreal anti-VEGF injection is effective for ROP. Preoperative fundus hemorrhage and long duration of oxygen therapy may increase the risk of ROP recurrence, and further studies are needed to investigate the influence of gestational hypertension on the recurrence of ROP.

导出引用

郝庆飞, 陈静, 阮鹏, 李高攀, 张静, 陈浩明, 郭宏湘, 孙晓娟, 程秀永. 玻璃体腔内注射抗血管内皮生长因子治疗早产儿视网膜病复发的危险因素分析[J]. 中国当代儿科杂志. 2022, 24(11): 1207-1212 https://doi.org/10.7499/j.issn.1008-8830.2205011

HAO Qing-Fei, CHEN Jing, RUAN Peng, LI Gao-Pan, ZHANG Jing, CHEN Hao-Ming, GUO Hong-Xiang, SUN Xiao-Juan, CHENG Xiu-Yong. Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity[J]. Chinese Journal of Contemporary Pediatrics. 2022, 24(11): 1207-1212 https://doi.org/10.7499/j.issn.1008-8830.2205011

参考文献

1 Blencowe H, Lawn JE, Vazquez T, et al. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010[J]. Pediatr Res, 2013, 74(Suppl 1): 35-49. PMID: 24366462. PMCID: PMC3873709. DOI: 10.1038/pr.2013.205.
2 Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity[J]. N Engl J Med, 2012, 367(26): 2515-2526. PMID: 23268666. PMCID: PMC3695731. DOI: 10.1056/NEJMra1208129.
3 Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity[J]. Arch Ophthalmol, 2005, 123(3): 311-318. PMID: 15767472. DOI: 10.1001/archopht.123.3.311.
4 Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity[J]. Ophthalmic Surg Lasers Imaging, 2007, 38(3): 233-237. PMID: 17552391. DOI: 10.3928/15428877-20070501-09.
5 Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. PMID: 21323540. PMCID: PMC3119530. DOI: 10.1056/NEJMoa1007374.
6 Süren E, ?zkaya D, ?etinkaya E, et al. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment[J]. Int Ophthalmol, 2022, 42(6): 1905-1913. PMID: 35094229. DOI: 10.1007/s10792-021-02188-z.
7 Gangwe AB, Agrawal D, Gangrade AK, et al. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity[J]. Indian J Ophthalmol, 2021, 69(8): 2171-2176. PMID: 34304203. PMCID: PMC8482928. DOI: 10.4103/ijo.IJO_3016_20.
8 Sankar MJ, Sankar J, Mehta M, et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity[J]. Cochrane Database Syst Rev, 2016, 2: CD009734. PMID: 26932750. DOI: 10.1002/14651858.CD009734.pub2.
9 Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors[J]. Ophthalmology, 2017, 124(8): 1156-1164. PMID: 28412066. DOI: 10.1016/j.ophtha.2017.03.018.
10 Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition[J]. Ophthalmology, 2021, 128(10): e51-e68. PMID: 34247850. DOI: 10.1016/j.ophtha.2021.05.031.
11 中华医学会眼科学分会眼底病学组. 中国早产儿视网膜病变筛查指南(2014年)[J]. 中华眼科杂志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
12 龙洋, 万伟伟, 刘宏卓, 等. 减量阿柏西普玻璃体腔注射治疗早产儿视网膜病变的疗效评估[J]. 中华实验眼科杂志, 2021, 39(1): 47-52. DOI: 10.3760/cma.j.cn115989-20200705-00477.
13 Good WV, Hardy RJ, Dobson V, et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study[J]. Pediatrics, 2005, 116(1): 15-23. PMID: 15995025. DOI: 10.1542/peds.2004-1413.
14 Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs[J]. Pediatrics, 2005, 115(5): e518-e525. PMID: 15805336. DOI: 10.1542/peds.2004-1180.
15 Ling KP, Liao PJ, Wang NK, et al. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy[J]. Retina, 2020, 40(9): 1793-1803. PMID: 31800460. DOI: 10.1097/IAE.0000000000002663.
16 Karmouta R, Altendahl M, Romero T, et al. Association between social determinants of health and retinopathy of prematurity outcomes[J]. JAMA Ophthalmol, 2022, 140(5): 496-502. PMID: 35420651. PMCID: PMC9011172. DOI: 10.1001/jamaophthalmol.2022.0667.
17 Fadakar K, Mehrabi Bahar M, Riazi-Esfahani H, et al. Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence[J]. Int Ophthalmol, 2022, 42(7): 2017-2028. PMID: 35059928. DOI: 10.1007/s10792-021-02198-x.
18 Yu CW, Popovic MM, Dhoot AS, et al. Demographic risk factors of retinopathy of prematurity: a systematic review of population-based studies[J]. Neonatology, 2022, 119(2): 151-163. PMID: 35124682. DOI: 10.1159/000519635.
19 Rasoulinejad SA, Montazeri M. Retinopathy of prematurity in neonates and its risk factors: a seven year study in northern Iran[J]. Open Ophthalmol J, 2016, 10: 17-21. PMID: 27014382. PMCID: PMC4780469. DOI: 10.2174/1874364101610010017.
20 Slidsborg C, Jensen A, Forman JL, et al. Neonatal risk factors for treatment-demanding retinopathy of prematurity: a Danish national study[J]. Ophthalmology, 2016, 123(4): 796-803. PMID: 26854038. DOI: 10.1016/j.ophtha.2015.12.019.
21 Lyu J, Zhang Q, Chen CL, et al. Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors[J]. Invest Ophthalmol Vis Sci, 2017, 58(3): 1719-1725. PMID: 28324112. DOI: 10.1167/iovs.16-20680.
22 Tong Q, Yin H, Zhao M, et al. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab[J]. BMC Ophthalmol, 2018, 18(1): 150. PMID: 29940900. PMCID: PMC6019321. DOI: 10.1186/s12886-018-0815-1.
23 Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins[J]. Proc Natl Acad Sci U S A, 1995, 92(23): 10457-10461. PMID: 7479819. PMCID: PMC40630. DOI: 10.1073/pnas.92.23.10457.
24 Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial[J]. JAMA Pediatr, 2018, 172(3): 278-286. PMID: 29309486. PMCID: PMC5840003. DOI: 10.1001/jamapediatrics.2017.4838.
25 Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity[J]. Cochrane Database Syst Rev, 2018, 1(1): CD009734. PMID: 29308602. PMCID: PMC6491066. DOI: 10.1002/14651858.CD009734.pub3.
26 Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment[J]. Retina, 2015, 35(4): 675-680. PMID: 25768252. DOI: 10.1097/IAE.0000000000000578.
27 Chan JJT, Lam CPS, Kwok MKM, et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy[J]. Sci Rep, 2016, 6: 27082. PMID: 27256987. PMCID: PMC4891718. DOI: 10.1038/srep27082.
28 Chen SN, Lian I, Hwang YC, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab[J]. Retina, 2015, 35(4): 667-674. PMID: 25462435. DOI: 10.1097/IAE.0000000000000380.
29 Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans[J]. Am J Ophthalmol, 2012, 154(4): 682-686.e2. PMID: 22818800. DOI: 10.1016/j.ajo.2012.03.047.